U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

People with macular degeneration and other forms of central vision loss can see details like text and faces with this device.

Please provide your email address to receive an email when new articles are posted on . The Foundation Fighting Blindness and the Nixon Visions Foundation are working together to launch the Nixon ...

Outlook Therapeutics received notice that the Food and Drug Administration can't approve its biologics license application for a drug designed to treat macular degeneration.

The age-related macular degeneration (AMD) market in the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK ...

Please provide your email address to receive an email when new articles are posted on . Researchers from the National Eye Institute found TIMP3 variants cause atypical presentations of Sorsby fundus ...

Outlook Therapeutics shares slid after the company's macular degeneration drug was once again rejected by the Food and Drug Administration. The stock dropped 71% to 45 cents a share in after-hours ...

HealthDay News — The Pooled Cohort Equations (PCE) cardiovascular risk score stratifies risk for multiple ocular diseases, according to a study published online Dec. 29 in Ophthalmology.

Retinal drusen are yellow/white-colored spots seen under the retina of your eye that are made up of proteins and a type of fat called lipids. The retina is the layer of cells lining the inside surface ...

Four words you never want to hear from the eye doctor are retinitis pigmentosa and macular degeneration. Both are genetic disorders that can cause loss of vision and neither has a cure. A team of ...